Michael Gelband’s Generate Biomedicines GENB Stock Holding History

Michael Gelband’s Portfolio GENB Stock Details GENB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-311,986	Closed	-$3.9M	–	2224
2026 Q1	$3.9M	Buy	+311,986	New	+$3.81M	0.03%	515

Other funds holding GENB

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Michael Gelband's GENB Position: Q2 2026 in Review

Michael Gelband sold out of Generate Biomedicines (GENB) in Q2 2026, closing a stake of 311,986 shares — an estimated $3.9M sold.

Michael Gelband first reported a position in GENB in Q1 2026 and held it in 1 quarter. The position peaked at $3.9M in Q1 2026. 85 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

Michael Gelband reported no remaining Generate Biomedicines position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 311,986 Generate Biomedicines shares in Q2 2026, an estimated $3.9M.
Michael Gelband first reported a position in Generate Biomedicines in Q1 2026 and held it in 1 quarter.
Michael Gelband's Generate Biomedicines position peaked at $3.9M in Q1 2026.
85 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.